Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company focused on innovative treatments for inflammatory diseases, will be presenting at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 2:40 p.m. ET. Attendees can access the live webcast through the Investors section of the Connect Biopharma website, where a replay will also be available for 90 days post-conference.

Headquartered in San Diego, California, Connect Biopharma aims to revolutionize the treatment landscape for conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD) through its proprietary drug, rademikibart. This next-generation antibody targets IL-4R?, addressing critical needs in the management of acute exacerbations of asthma and COPD. Currently, the company is conducting global clinical trials to evaluate the efficacy and safety of rademikibart, which promises a significant impact given the large unmet medical demand in these therapeutic areas.

In a strategic move to expand its market reach, Connect Biopharma has entered into an exclusive licensing agreement with Simcere Pharmaceutical Co., Ltd. for the commercialization of rademikibart in Greater China. This partnership positions Connect to receive milestone payments totaling approximately $110 million contingent on the successful achievement of specific development and regulatory phases. Additionally, the agreement includes provisions for tiered royalties based on future net sales in the region.

Connect Biopharma remains committed to advancing its pipeline and addressing the needs of patients grappling with inflammatory conditions, while actively engaging with the investor community to share its progress and future plans. For further details, visit www.connectbiopharma.com.

Connect Biopharma (Nasdaq: CNTB) stands at a pivotal moment as it prepares to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. Investors should closely watch this event, as it provides an opportunity for the company to share updates on its lead product, rademikibart, which targets key aspects of inflammatory diseases, specifically asthma and COPD.

Currently, the biopharmaceutical sector faces significant opportunities, especially in addressing unmet needs in chronic diseases. With asthma and COPD affecting millions globally, rademikibart’s development could position Connect Biopharma as a leader in this market if clinical trials prove successful. The company's collaboration with Simcere Pharmaceutical in Greater China not only strengthens its market position but also represents a future revenue stream with potential milestone payments and royalties.

As Connect Biopharma approaches this conference, the key aspects to monitor include updates on clinical trial results, partnerships, and regulatory progress. Observing the management's tone and strategy during the presentation could provide investors with insights into the company’s growth trajectory and its approach to combating competitive pressures in the biopharmaceutical space.

Investors should analyze the company’s fundamentals alongside upcoming news, as the market may respond significantly to any announcements about trial successes or patient population data. Additionally, given the volatile nature of biopharma stocks, a cautious approach is recommended. Diversifying exposure to the sector while maintaining a close watch on Connect’s progress could be prudent as rademikibart advances through its clinical phases.

In summary, Connect Biopharma offers potential upside with its innovative pipeline, but investors should remain vigilant about the inherent risks of clinical-based companies, especially leading up to significant presentations like the one at Oppenheimer's conference.